Lineage Cell Therapeutics
LCTX
LCTX
105 hedge funds and large institutions have $52.1M invested in Lineage Cell Therapeutics in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 71 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
60% less capital invested
Capital invested by funds: $130M → $52.1M (-$78.3M)
75% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 71
Holders
105
Holding in Top 10
3
Calls
$20K
Puts
–
Top Buyers
| 1 | +$333K | |
| 2 | +$237K | |
| 3 | +$105K | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$95.6K |
| 5 |
JG
Jefferies Group
New York
|
+$77.5K |
Top Sellers
| 1 | -$3.91M | |
| 2 | -$2.84M | |
| 3 | -$1.09M | |
| 4 |
BlackRock
New York
|
-$727K |
| 5 |
Bank of New York Mellon
New York
|
-$424K |